Characterization of CTL Recognized Epitopes on Human Breast Tumors
Annual rept. 19 Aug 1998-18 Aug 1999
TEXAS UNIV AT HOUSTON
Pagination or Media Count:
Studies during the last granting period were focused on the activating ability of tumor Ag identified from HER-2 and FBP for T cells from breast cancer patients. Ongoing studies focuses on improvement of Ag presentation and enhanced activation of CTL functions concludes that 1 IL-l2 is required for early and rapid IFN- induction in response to tumor Ag. This was established using both randomly selected breast cancer patients, and patients vaccinated with HER-2 tumor Ag, E75 using GM-CSF as adjuvant 2 Tumor Ag such as E75 induce the angiostaticanti-angiogenic chemokine IP-lO from responder lymphocytes 3. Enhanced Ag presentation and immunogenicity can be achieved by inducing SerThr phosphorylation of HER-2.
- Medicine and Medical Research